News & Updates

Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin and oxaliplatin (FOLFOX) as first-line treatment significantly improves overall survival (OS) vs transarterial chemoembolization (TACE) in patients with large, unresectable hepatocellular carcinoma (HCC), a phase III trial in China has shown.

Some patients with irritable bowel syndrome (IBS) may achieve symptom reduction, particularly diarrhoea, on a gluten-free diet, and who these patients are may be identified by using the antigliadin immunoglobulin G (IgG) as a biomarker, according to a study.

Among healthy individuals, a fasting plasma glucose (FPG) concentration within the range of 90–99 mg/dL increases the risk of type 2 diabetes, a new Japan study has found.

Intravitreal bevacizumab (IVB) injections induce short-lived visual benefit but ease the need for vitrectomy in proliferative diabetic retinopathy (PDR) patients with vitreous haemorrhage (VH) who had undergone prior complete panretinal photocoagulation (PRP), a recent study has found.

Among patients with type 2 diabetes (T2D), women appear to be at greater risk of accelerated cognitive decline than men, as reported in a study. This risk increase can be partly explained by depressive symptoms being greater among women.

Pembrolizumab extended recurrence-free survival (RFS) in patients with high-risk stage II melanoma who had undergone complete resection, interim analysis results of the phase III KEYNOTE-716 trial showed.

Panbio, a rapid antigen test for SARS-CoV-2, has good specificity but limited sensitivity, as shown in a study. As such, all negative tests have to be confirmed with RT-PCR, especially in the presence of related symptoms, in settings with high community infection rate, and in cases of direct contact with confirmed COVID-19 patients.

The COVID-19 pandemic has evidently affected the care and well-being of cancer patients, particularly those with advanced stages, reveals a recent study.

Results of a randomized, double-blind, placebo-controlled trial show no benefit with mirtazapine, given with normal clinical care, for treatment of clinically significant agitation in patients with dementia compared with placebo, with a potentially higher mortality observed with the use of mirtazapine.